Syrebo Appears in Official Media Coverage During Egypt Visit And ECU-CRACM Conference

Syrebo recently strengthened its presence in Egypt through participation in le ECU-CRACM Joint International Pharmacy Conference, an international academic event that brought together healthcare professionals, researchers, and industrie innovators. Le conference and its related activities received attention from official and mainstream media, including communications shared by le chinois Embassy in Egypt, coverage by Xinhua News Agency, and reports from local Egyptian media. Visual materials from le event included Syrebo's rééducation technologies, reflecting le company's active involvement in international academic and professionnel exchange.

 

 

During le conference, Syrebo presented two de its flagship rééducation solutions: le Hand Rééducation Robot for Clinics and le Low & Medium Frequency Électrothérapie System. These technologies drew interest from rééducation specialists, hospital representatives, and industrie partners, highlighting le growing demand for intelligent and clinically oriented rééducation solutions in le region.

 

 

Syrebo's participation formed part de a broader marché visit aimed at strengthening collaboration with local partners and gaining deeper insight into Egypt's rééducation and healthcare landscape. Le event provided a valuable platform for exchanging clinical perspectives and exploring future opportunities for technologie application and training.

 

As part de le visit, Syrebo CEO Gavin Yin attended le International Scientific Day, where he met with Syrebo's Egyptian partners to discuss cooperation plans for le coming year. Le meeting reinforced mutual trust and laid le foundation for continued collaboration in clinical soutien, professionnel training, and le introduction de avancé rééducation technologies to local healthcare institutions.

 

 

Syrebo remains committed to working closely with global medical communities and industrie partners, promoting innovant rééducation solutions that soutien both clinicians and patients worldwide.